KinderCare misses, updates 2026 guidance for revenue hit, margin gains from center consolidations

KinderCare misses Q2 2026 estimates with EPS $0.08 and updates 2026 guidance for revenue hit, margin gains from center consolidations

• Non-GAAP EPS $0.08 declined 64% YoY, causing KinderCare Learning to miss Q2 2026 earnings estimates.
• Q2 revenue totaled $697.5M, roughly flat year over year, modestly below estimates and prior-year level.
• Revenue $698M, slightly below last year, as enrollment softness offset by pricing and B2B.
• Adjusted EBITDA $63M and adjusted EPS $0.08, both down significantly YoY on lower occupancy.
• Full-year guidance updated: revenue $2.66–$2.70B, adjusted EBITDA $200–$220M, adjusted EPS $0.05–$0.15.
• Guidance incorporates $57M annualized revenue headwind but $8M EBITDA benefit from 80–85 center consolidations.
• Same-center occupancy 68.6%, down 240 basis points YoY, with total enrollment declining 4%.
• Champions revenue grew 13% YoY, while Learning Adventures enrichment revenue nearly doubled versus last year.
• Crim premium brand strengthening, with summer camp enrollment up ~26% and expansion into California underway.
• Gross margin not disclosed; SG&A improved to 10.5% of revenue, down 76 basis points YoY.
• Free cash flow expected below $10M in 2026, pressured by $20–$25M lease exit payments.
• Management tone optimistic: confident optimization improves 2027 positioning but acknowledging near-term volatility and weaker earnings.
• Main concern: Ongoing enrollment weakness and execution risk around center consolidations and lease exits.
• Mixed quarter, driven by enrollment softness offset by B2B growth and pricing.

https://finviz.com/stock?t=KLC&p=d#:~:text=KinderCare%20misses%20Q2,and%20pricing.

Positive interim eGFR data from ORIGIN 3 in FDA docs drives VERA premarket surge

 

• Interim placebo-adjusted annualized eGFR slope +5.2 mL/min/1.73m² at week 52 (SE 1.6).
• Favorable vs. competitor Otsuka’s +4.7 at 104 weeks; drug arm improved from -0.3 to +0.9.
• Bolsters case for full approval of TRUTAKNA (atacicept) in IgA nephropathy after July accelerated approval.
• Catches shorts off-guard with high short interest; data from post-approval FDA review documents.
• Follows Aug 10 Q2 update on FDA alignment for earlier eGFR analysis in Q3 2026.
• No new company PR today; trader analysis on X highlighted the numbers as sentiment shift.

https://finviz.com/stock?t=VERA&p=d

Valneva: EMA marketing authorization application for co-developed Lyme vax candidate with Pfizer

 Valneva announces that the European Medicines Agency has validated the marketing authorization application for its co-developed Lyme disease vaccine candidate with Pfizer.

https://finviz.com/stock?t=VALN&p=d

Eton beats, ups gidance

 

Eton beats Q2 2026 estimates with non-GAAP EPS $0.43 (+530% YoY), revenue $37.6M (+99% YoY), raises 2026 revenue guidance above $145M and expands margins

• Revenue $37.6M, up 99% YoY, driven by Hemangiol relaunch and pediatric endocrinology growth.
• Adjusted EBITDA margin expanded to 43% from 16%, with guidance raised above 35% for 2026.
• Full-year 2026 revenue guidance increased to >$145M from >$120M, reflecting outperformance and sustained momentum.
• Hemangiol already Eton’s largest product; ~95% patient transition completed, now targeting off-label conversion growth.
• ASN001 topical hemangioma therapy acquired; single low-risk bridging study planned before 2027 NDA submission.
• Desmoda launch tracking ahead of internal patient targets; peak sales view $40–50M unchanged.
• Galzin and Wilson disease franchise growing; ET-700 extended-release zinc shows >$100M potential pending pivotal success.
• Impavido leishmaniasis drug added via low-upfront deal; expect multi-million revenue contribution despite profit-sharing.
• Balance sheet solid with $26.8M cash; prioritizing business development and accelerated debt repayment.
• Key risks: Hemangiol patent expiry 2028, negative-margin ex-US Increlex sales, rising R&D for pipeline.
• Main concern: Maintaining growth and profitability as Hemangiol faces 2028 patent expiry and pipeline investment ramps.
• Strong quarter, driven by Hemangiol-fueled revenue growth and substantial operating leverage across the rare disease portfolio.

https://finviz.com/stock?t=ETON&p=d

https://nypost.com/2026/08/13/opinion/doctors-profited-from-fraud-and-mutilation-in-minor-trans-treatments-hhs-report/

https://nypost.com/2026/08/14/us-news/uft-boss-calls-out-mamdani-admin-after-embarrassing-nyc-school-reading-scores/

https://www.zerohedge.com/energy/saudi-oil-fleet-increasingly-going-dark-due-houthi-blockade